Weinzimer Stuart A, Tamborlane William V
Department of Pediatrics, Center for Clinical Investigation, Yale University School of Medicine, New Haven, Connecticut 06520-8064, USA.
Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):118-22. doi: 10.1097/MED.0b013e3282f7960b.
Recent developments in technology have ushered in a new era of managing type 1 diabetes. Continuous glucose monitoring is rapidly becoming an accepted adjunct to traditional self-monitoring of plasma glucose, and the marriage of continuous glucose sensors to continuous subcutaneous insulin infusion is the first step towards the development of a true artificial pancreas. The purpose of this review is to familiarize the reader with the new glucose sensors and discuss the literature evaluating their accuracy and effectiveness.
Current models of continuous glucose sensors are still less accurate than traditional methods of blood glucose monitoring but provide information regarding trends that cannot be obtained with blood testing. Short-term studies of continuous glucose sensors have demonstrated reduction in glycosylated hemoglobin levels and time spent in hypo- and hyperglycemic ranges. Patient acceptance and satisfaction with sensors has been shown to depend on the quality of the data, comfort of wear, and ease of use.
Sensor-augmented pump therapy represents a landmark improvement in diabetes treatment and will likely become the standard of care. Future work should focus on improvements in sensor accuracy and development of user-friendly algorithms to assist patients with self-management.
技术的最新发展开创了1型糖尿病管理的新纪元。持续葡萄糖监测正迅速成为传统血浆葡萄糖自我监测的一种被广泛接受的辅助手段，而持续葡萄糖传感器与持续皮下胰岛素输注的结合是迈向真正人工胰腺发展的第一步。本综述的目的是使读者熟悉新型葡萄糖传感器，并讨论评估其准确性和有效性的文献。
当前的持续葡萄糖传感器模型仍不如传统血糖监测方法准确，但能提供通过血液检测无法获得的血糖变化趋势信息。持续葡萄糖传感器的短期研究表明，糖化血红蛋白水平降低，低血糖和高血糖范围的时间减少。已证明患者对传感器的接受度和满意度取决于数据质量、佩戴舒适度和易用性。
传感器增强型泵疗法代表了糖尿病治疗的一项里程碑式进展，很可能成为护理标准。未来的工作应集中在提高传感器准确性以及开发便于用户使用的算法，以帮助患者进行自我管理。
